A Hybrid Implementation-effectiveness Randomized Trial of CYP2D6-guided Postoperative Pain Management

Overview

Journal Genet Med

Publisher Elsevier

Specialty Genetics

Date 2021 Jan 9

PMID 33420349

Citations 17

Authors

Cameron D Thomas

Hari K Parvataneni

Chancellor F Gray

Justin T Deen

Hernan A Prieto

Luis F Pulido

Amanda R Elsey

Erica N Elwood

Petr Starostik

Yan Gong

Roger B Fillingim

Julie A Johnson

Larisa H Cavallari

Affiliations

Soon will be listed here.

Abstract

Purpose: Cytochrome P450 2D6 (CYP2D6) genotype-guided opioid prescribing is limited. The purpose of this type 2 hybrid implementation-effectiveness trial was to evaluate the feasibility of clinically implementing CYP2D6-guided postsurgical pain management and determine that such an approach did not worsen pain control.

Methods: Adults undergoing total joint arthroplasty were randomized 2:1 to genotype-guided or usual pain management. For participants in the genotype-guided arm with a CYP2D6 poor (PM), intermediate (IM), or ultrarapid (UM) metabolizer phenotype, recommendations were to avoid hydrocodone, tramadol, codeine, and oxycodone. The primary endpoints were feasibility metrics and opioid use; pain intensity was a secondary endpoint. Effectiveness outcomes were collected 2 weeks postsurgery.

Results: Of 282 patients approached, 260 (92%) agreed to participate. In the genotype-guided arm, 20% had a high-risk (IM/PM/UM) phenotype, of whom 72% received an alternative opioid versus 0% of usual care participants (p < 0.001). In an exploratory analysis, there was less opioid consumption (200 [104-280] vs. 230 [133-350] morphine milligram equivalents; p = 0.047) and similar pain intensity (2.6 ± 0.8 vs. 2.5 ± 0.7; p = 0.638) in the genotype-guided vs. usual care arm, respectively.

Conclusion: Implementing CYP2D6 to guide postoperative pain management is feasible and may lead to lower opioid use without compromising pain control.

Citing Articles

A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) Trial.

Smith D, Beyene R, Kolm P, Young T, Zifa S, Natividad V Clin Transl Sci. 2025; 18(2):e70154.

PMID: 39921243 PMC: 11805805. DOI: 10.1111/cts.70154.

Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive Genotyping in Cancer Palliative Care.

Cho Y, Karrison T, Jack M, Choksi A, Knoebel R, Yeo K J Pain Res. 2024; 17:4187-4196.

PMID: 39717756 PMC: 11664000. DOI: 10.2147/JPR.S488416.

Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials.

Hamilton M, Mathieson S, Jamshidi M, Wang A, Lee Y, Gnjidic D Drugs. 2024; 85(3):385-396.

PMID: 39702868 PMC: 11891105. DOI: 10.1007/s40265-024-02116-2.

Associations between (pharmaco-)genetic markers and postoperative pain after inguinal hernia repair - a prospective study protocol.

Wiss F, Dietz U, Thalheimer A, Lamm S, Rosenberg R, Allemann S BMC Med Genomics. 2024; 17(1):286.

PMID: 39696400 PMC: 11658386. DOI: 10.1186/s12920-024-02064-6.

Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients.

Hoffecker G, Keat K, Mulugeta-Gordon L, Risman M, Verma S, Deagostino-Kelly M Pharmacogenomics. 2024; 25(14-15):587-594.

PMID: 39545769 PMC: 11703490. DOI: 10.1080/14622416.2024.2428585.

References

Ciszkowski C, Madadi P, Phillips M, Lauwers A, Koren G . Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009; 361(8):827-8. DOI: 10.1056/NEJMc0904266. View

Hicks J, Swen J, Gaedigk A . Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab. 2014; 15(2):218-32. DOI: 10.2174/1389200215666140202215316. View

Han B, Compton W, Blanco C, Crane E, Lee J, Jones C . Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med. 2017; 167(5):293-301. DOI: 10.7326/M17-0865. View

Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder S . Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006; 368(9536):704. DOI: 10.1016/S0140-6736(06)69255-6. View

Volpe D, Tobin G, Mellon R, Katki A, Parker R, Colatsky T . Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011; 59(3):385-90. DOI: 10.1016/j.yrtph.2010.12.007. View

Curran G, Bauer M, Mittman B, Pyne J, Stetler C . Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012; 50(3):217-26. PMC: 3731143. DOI: 10.1097/MLR.0b013e3182408812. View

Lopes G, Bielinski S, Moyer A, Black Iii J, Jacobson D, Jiang R . Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics. Pharmgenomics Pers Med. 2020; 13:71-79. PMC: 7081062. DOI: 10.2147/PGPM.S239222. View

Crews K, Gaedigk A, Dunnenberger H, Leeder J, Klein T, Caudle K . Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014; 95(4):376-82. PMC: 3975212. DOI: 10.1038/clpt.2013.254. View

Kalso E, Edwards J, Moore A, McQuay H . Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 112(3):372-380. DOI: 10.1016/j.pain.2004.09.019. View

10.

Davis M, Varga J, Dickerson D, Walsh D, LeGrand S, Lagman R . Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer. 2003; 11(2):84-92. DOI: 10.1007/s00520-002-0385-9. View

11.

Stamer U, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A . Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003; 105(1-2):231-8. DOI: 10.1016/s0304-3959(03)00212-4. View

12.

Jhun E, Apfelbaum J, Dickerson D, Shahul S, Knoebel R, Danahey K . Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019; 20(11):813-827. PMC: 6949515. DOI: 10.2217/pgs-2019-0040. View

13.

Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P . Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351(27):2827-31. DOI: 10.1056/NEJMoa041888. View

14.

Dowell D, Haegerich T, Chou R . CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016; 315(15):1624-45. PMC: 6390846. DOI: 10.1001/jama.2016.1464. View

15.

Mosley S, Hicks J, Portman D, Donovan K, Gopalan P, Schmit J . Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials. 2018; 68:7-13. PMC: 5899651. DOI: 10.1016/j.cct.2018.03.001. View

16.

Wick E, Grant M, Wu C . Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and Techniques: A Review. JAMA Surg. 2017; 152(7):691-697. DOI: 10.1001/jamasurg.2017.0898. View

17.

Adams E, Breiner S, Cicero T, Geller A, Inciardi J, Schnoll S . A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006; 31(5):465-76. DOI: 10.1016/j.jpainsymman.2005.10.006. View

18.

Truong T, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel R . The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019; 106(6):1179-1183. PMC: 7214100. DOI: 10.1002/cpt.1567. View

19.

Kim K, Murray M, Tu W, Robarge J, Ding Y, Brater D . Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur J Clin Pharmacol. 2012; 68(11):1483-91. DOI: 10.1007/s00228-012-1280-z. View

20.

Sjoveian A, Leegaard M . Hip and knee arthroplasty - patient's experiences of pain and rehabilitation after discharge from hospital. Int J Orthop Trauma Nurs. 2017; 27:28-35. DOI: 10.1016/j.ijotn.2017.07.001. View